Innovent Biologics (1801) Collaboration summary

Opening remarks and agenda

• The call opened with an introduction of the strategic collaboration, including presentations from key executives and a Q&A session, with conference calls held in both Chinese and English.

Objectives of the partnership

• The partnership aims to accelerate global development and commercialization of next-generation IO and ADC oncology assets, supporting the goal to become a global premier biopharma by 2030.

• Focus on building a robust pipeline, expanding global footprint, and delivering transformative, high-quality cancer treatments to patients worldwide.

Partner introductions and roles

• Takeda, a global biopharma leader with deep commercial and R&D expertise, operates in 80+ countries and brings significant oncology leadership.

• Innovent contributes pioneering research and proven R&D in IO and ADC, leveraging integrated global and China-based clinical platforms.

• Takeda will lead co-development and co-commercialization of IBI363 in the U.S. and hold exclusive rights outside Greater China and the U.S.; Takeda receives exclusive global rights for IBI343 and an option for IBI3001 outside Greater China.